https://medicine.ouhsc.edu/directory Parent Page: Directory id: 22535 Active Page: Detailsid:23325

Directory

Categories

Shailendra Dwivedi, PhD
Obstetrics and Gynecology

Shailendra Dwivedi, PhD

Assistant Professor
Adjunct Assistant Professor, Pathology

BSEB #335
941 Stanton L Young Blvd
Oklahoma City, OK 73104 

405-271-8001 Ext. 37470

shailendra-dwivedi@ouhsc.edu

I am a young investigator with a versatile skill set in cancer biology, cell signaling, nuclear receptor signaling, and non-coding RNA. During my doctoral research, I concentrated on comprehending cellular communication, including analyzing BCRABL and IGF-RI signaling in cancer and determining the therapeutic potential of new candidate drugs in Chronic Myeloid Leukemia and Breast cancer. Presently, my research focuses on investigating molecular signaling in ovarian cancer and uterine carcinosarcoma, with an emphasis on discovering innovative therapeutic methods. I have extensively researched and identified the importance of non-coding RNA, particularly micro-RNA and long non-coding RNA, in ovarian cancer. Through my research, I aim to develop novel treatments for women with gynecologic malignancies, thereby enhancing their quality of life.

Academic Section(s):

Gynecologic Oncology

Education:

 

  • Ph.D. Life Science, Department of Endocrinology and Drug Target Discovery and Development), CSIR-CDRI/Jawaharlal Nehru University, India
  • Master of Science- Biotechnology, V.B.S. P. University, Jaunpur, UP, India
  • Bachelor of Science in Chemistry, Botany from D.D.U. Gorakhpur University, Gorakhpur, UP, India

 

Positions/Scientific Appointments

2005-2007       Research Assistant, VP Chest Institute, University of Delhi, Delhi – 07, India

2007-2009       Junior Research Fellow, CSIR-CDRI Lucknow, UP, India

2009-2012       Senior Research Fellow, CSIR-CDRI Lucknow, UP, India

2012- 2013      Assistant Professor, Department of Biotechnology, IT College, Lucknow, UP India

2013-2018       Postdoctoral Research Fellow, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

2018- 2023      Assistant Professor of Research, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

2023-Present   Assistant Professor, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

                                                                                                                                       

 

Clinical/Research Interests:

For the past 15 years, I have devoted my research to developing novel therapeutic approaches for targeting cancer. Non-coding RNAs are known to play a key role in the development of gynecological malignancies like ovarian cancer and uterine carcinosarcoma. However, their therapeutic potential has not been well explored and is the focus of my ongoing research. Additionally, I am also exploring non-coding RNA's (long non-coding RNA and micro-RNA) role in cancer metabolism, as well as in the tumor microenvironment. My lab's primary objective is to gain a deeper understanding of molecular pathways governed by non-coding RNAs and apply these discoveries to improve cancer diagnosis and treatment. My research ultimately aims to produce novel non-coding RNA-based therapeutic strategies for cancer-afflicted patients.

Funding:

PHF Pilot Grant (July 2022-June 2023)

Tittle - Dissecting the role of miR-195 in ovarian cancer stemness

Role: Principal Investigator

OCAST FY21 Competition Health Research Award (November 2021 to October 2024),

Tittle - Targeting NNT-AS1 for Ovarian Cancer Therapy.

Role: Principal Investigator

NCI-R21 (1R21CA280507-01)

Role of miR-195 in Chemo-Resistant Ovarian Cancer

Role: Principal Investigator

DoD OCA-ECI (09/01/2023-08/31/2027)

Title: miR-195 Re-Expression: A Therapeutic Strategy for Chemo-Resistant Ovarian Cancer

Role: Principal Investigator

Select Honors and Accomplishments:

  • Associate member of Stephenson Cancer Center (Cancer Biology research program)
  • Bruce Patsner Grant Award for Innovative Research & Technology (April 2017 to April 2018), from the Foundation for Women’s Cancer supported by the Dr. Bruce Patsner.
  • Qualified for Fellowship by Indian Council for Medical Research (ICMR), Government of India, 2007
  • Qualified in the National Eligibility Test (NET) and declared eligible for Fellowship and Lectureship by Council for Scientific and Industrial Research (CSIR), Government of India, 2006

Select Publications:

 

  1. Rao, G., S.K.D. Dwivedi, Y. Zhang, A. Dey, K. Shameer, R. Karthik, S. Srikantan, M.N. Hossen, J.D. Wren, M. Madesh, J.T. Dudley, R. Bhattacharya, and P. Mukherjee, MicroRNA-195 controls MICU1 expression and tumor growth in ovarian cancer. EMBO Rep, 2020. 21(10): p. e48483. PMC7534609
  2. Dwivedi, S.K.D., G. Rao, A. Dey, P. Mukherjee, J.D. Wren, and R. Bhattacharya, Small Non-Coding-RNA in Gynecological Malignancies. Cancers (Basel), 2021. 13(5). PMC7961667
  3. Neizer-Ashun, F., S.K.D. Dwivedi, A. Dey, E. Thavathiru, W.L. Berry, S.P. Lees-Miller, P. Mukherjee, and R. Bhattacharya, KRCC1, a modulator of the DNA damage response. Nucleic Acids Res, 2022. 50(19): p. 11028-11039. PMC9638924
  4. Zhang, Y., C.K. Elechalawar, W. Yang, A.N. Frickenstein, S. Asfa, K.M. Fung, B.N. Murphy, S.K. Dwivedi, G. Rao, A. Dey, S. Wilhelm, R. Bhattacharya, and P. Mukherjee, Disabling partners in crime: Gold nanoparticles disrupt multicellular communications within the tumor microenvironment to inhibit ovarian tumor aggressiveness. Mater Today (Kidlington), 2022. 56: p. 79-95. PMC9523457
  5. Dwivedi, S.K.D., K. Shameer, A. Dey, S.B. Mustafi, X. Xiong, U. Bhattacharya, F. Neizer-Ashun, G. Rao, Y. Wang, C. Ivan, D. Yang, J.T. Dudley, C. Xu, J.D. Wren, P. Mukherjee, and R. Bhattacharya, KRCC1: A potential therapeutic target in ovarian cancer. FASEB J, 2020. 34(2): p. 2287-2300. PMC7018556
  6. Hossen, M.N., L. Wang, S.K.D. Dwivedi, Y. Zhang, G. Rao, C.K. Elechalwar, V. Sheth, A. Dey, S. Asfa, S.K. Gulla, C. Xu, K.M. Fung, J.D. Robertson, M. Bieniasz, S. Wilhelm, R. Bhattacharya, and P. Mukherjee, Gold Nanoparticles Disrupt the IGFBP2/mTOR/PTEN Axis to Inhibit Ovarian Cancer Growth. Adv Sci (Weinh), 2022. 9(31): p. e2200491. PMC9631030
  7. Banerjee Mustafi, S., P.K. Chakraborty, S.K. Dwivedi, K. Ding, K.M. Moxley, P. Mukherjee, and R. Bhattacharya, BMI1, a new target of CK2alpha. Mol Cancer, 2017. 16(1): p. 56. PMC5341428
  8. Chakraborty, P.K., S.B. Mustafi, X. Xiong, S.K.D. Dwivedi, V. Nesin, S. Saha, M. Zhang, D. Dhanasekaran, M. Jayaraman, R. Mannel, K. Moore, S. McMeekin, D. Yang, R. Zuna, K. Ding, L. Tsiokas, R. Bhattacharya, and P. Mukherjee, MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun, 2017. 8: p. 14634. PMC5477507
  9. Dwivedi, S.K., S.B. Mustafi, L.S. Mangala, D. Jiang, S. Pradeep, C. Rodriguez-Aguayo, H. Ling, C. Ivan, P. Mukherjee, G.A. Calin, G. Lopez-Berestein, A.K. Sood, and R. Bhattacharya, Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget, 2016. 7(12): p. 15093-104. PMC4924772

Publication Link:

https://www.ncbi.nlm.nih.gov/myncbi/shailendra.dwivedi.1/bibliography/public/